Overview of fluoroquinolone safety

Wolfson, John S.; Hooper, David C.

doi:10.1016/0002-9343(91)90330-z

Cited by 83 publications

(58 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 Additionally, it is considered to be a safe and effective treatment for acute infectious colitis. 2,3 Its lack of serious adverse effects has been an important factor in its use for what is usually a benign, self-limiting condition. Of 63,059 patients given oral ciprofloxacin, adverse effects occurred in 5.8% of patients, with 3.4% being of a gastrointestinal nature.…”

Section: Discussionmentioning

confidence: 99%

“…The drug is generally associated with mild, reversible elevation of liver enzymes and bilirubin in approximately 2% to 3% of patients. 2 In the pancreatic field, ciprofloxacin can be a useful tool as an empirical therapy in necrotizing pancreatitis to prevent secondary bacterial infection, [8][9][10][11] because ciprofloxacin penetrates the human pancreas very well. 12,13 However, ironically, it is claimed that the ciprofloxacin can, in rare cases, cause drug-induced pancreatitis.…”

Section: Discussionmentioning

confidence: 99%

“…5 Drug-induced pancreatitis is a rare cause of acute pancreatitis, accounting for approximately 2% to 5% of all cases of pancreatitis. [2][3][4]14 In our hospital, total number of acute pancreatitis patients during the study was 251. Out of 251 acute pancreatitis patients reported during the study, 11 cases were found to be drug-induced, accounting for 4.4% (11/251).…”

Section: Discussionmentioning

confidence: 99%

“…1 Generally, it is considered to be a safe and effective treatment of acute infectious colitis. 2,3 Additionally, it is a widely used empirical therapy for travelers' diarrhea. 4 However, ciprofloxacin can, in rare cases, cause druginduced pancreatitis.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis

Jeong

Kim

Lee

et al. 2013

European Journal of Internal Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis

Jeong

Kim

Lee

et al. 2013

European Journal of Internal Medicine

View full text Add to dashboard Cite

“…Fluoroquinolones represent a class of antimicrobials which has gained popularity because of their very impressive pharmacokinetics properties, efficacy, convenient oral dosage schedule, broad-spectrum anti-microbial activity and low incidence of adverse reactions (Goel et al, 1998;Walker et al, 1991;Wolfson and Hooper, 1991a;Kumar andGurumurthy, 2004, EMEA/CVMP/SAGAM, 2004;O'Brien et al, 2012). Ofloxacin, is a synthetic analogue of nalidixic acid which inhibit the bacterial enzyme…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of isoniazid with or without ofloxacin

2012

View full text Add to dashboard Cite

Objective of the resent study was to determine the effect of ofloxacin (OXC) on the pharmacokinetics of isoniazid (INH). Five healthy volunteers aged 18 39 years participated in this study after an informed consent. The study was carried out in two phases with an interval of one-week drug wash out period in between phases. In phase one (INH alone), each subject received 300mg of isoniazid (INH) with 350ml of water after an overnight fast. The subjects were made to fast 2 hours post drug. In phase two (INH + OXC), each subject was administered with 300mg of INH in combination with 200mg of OXC observing all the protocol in phase one. The concentration of INH in plasma, saliva and urine of the subjects at predetermined time intervals were measured spectrophotometrically in the two phases over a period of 0 - 48 hours. Various pharmacokinetics parameters were calculated. From the study it is evident that Ofloxacin (OXC) increased the rate and extent of absorption of isoniazid. The absorption half-life (t1/2a) and the maximum concentration and absorption time (Cmax, Tmax) of isoniazid (INH) were increased in the presence of OXC. The urinary excretion of isoniazid was also increased by ofloxacin. The salivary concentration of isoniazid was less than the corresponding plasma drug concentrations, a pattern also found in similar studies. Thus it can be concluded that Ofloxacin increases absorption kinetics and urinary excretion of Isoniazid.DOI: http://dx.doi.org/10.3329/icpj.v1i12.12449 International Current Pharmaceutical Journal 2012, 1(12): 403-409

show abstract

Ciprofloxacin-Induced Nephrotoxicity in Patients With Cancer

Rolston²,

Rubenstein

et al. 1993

Arch Intern Med

View full text Add to dashboard Cite

Nephrotoxicity associated with ciprofloxacin is uncommon. Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed. Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present. Allergic interstitial nephritis is believed to be the underlying pathological-process. Definitive diagnosis requires performance of renal biopsy, although this is not always feasible. An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.

show abstract

Overview of fluoroquinolone safety

Cited by 83 publications

References 143 publications

Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis

Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis

Pharmacokinetics of isoniazid with or without ofloxacin

Ciprofloxacin-Induced Nephrotoxicity in Patients With Cancer

Contact Info

Product

Resources

About